

**Elekta and GE HealthCare's MIM Software enter significant collaboration to deliver leading cancer treatment planning solutions**

*Strategic collaboration to develop advanced vendor-agnostic radiation oncology treatment applications using industry-leading auto-contouring and treatment planning software solutions*

STOCKHOLM – Elekta (EKTA-B.ST) and MIM Software Inc. (MIM), a leading provider of medical imaging management and artificial intelligence solutions, recently acquired by GE HealthCare, announce their collaboration to combine best-of-breed solutions for advanced treatment planning in the delivery of radiation therapy.

The strategic collaboration aims to accelerate innovation in software solutions that will benefit clinics with improved workflows, higher throughput, and enhanced user experience, while for patients, provide greater precision in their treatment and less time spent at the hospital.

Maurits Wolleswinkel, Elekta's President Linac and Software Solutions, said: "While this is an exciting step for both companies it's a significant development for radiation therapy clinics and their patients. This is a natural expansion of Elekta ONE, combining the best dose planning capabilities with MIM's proven track record of physician preferred tools. Clinically, it means delivering on improved automation and adaptive therapy planning, as well as greater speed and accuracy. And our vendor-agnostic philosophy ensures that all radiation therapy providers stand to gain from this collaboration."

The collaboration is expected to spur innovation within treatment planning and utilize Elekta's and MIM Software's respective strengths in regional markets to make solutions available globally.

Andrew Nelson, CEO of MIM Software, GE HealthCare, added "Since its beginning in 2003, MIM has played a key role in advancing precision medicine in radiation oncology."

Jonathan Piper, Chief Scientific Officer of MIM Software, GE HealthCare said: "We've listened to overwhelming customer requests for treatment planning software and proudly announce that we've risen to the challenge. This is a pivotal step towards streamlining clinical workflows, unlocking precision medicine, and expanding our impact on clinicians and patients worldwide."

See a live demo of Elekta ONE, including the new treatment applications that this strategic partnership already enables at ESTRO 2024, May 3-7 in Glasgow, UK at Elekta's booth #440.

###

**For further information, please contact:**

Mattias Thorsson, Vice President, Head of Corporate Communications

Tel: +46 70 865 8012, e-mail: [Mattias.Thorsson@elekta.com](mailto:Mattias.Thorsson@elekta.com)

Time zone: CET: Central European Time



---

Raven Canzeri, Global Director, Media Relations  
Tel: +1 770-670-2524, e-mail: [Raven.Canzeri@elekta.com](mailto:Raven.Canzeri@elekta.com)  
Time zone: ET: Eastern Time

**About Elekta**

As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,500 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit [elekta.com](http://elekta.com) or follow [@Elekta](https://twitter.com/Elekta) on "X", formerly known as Twitter.